This multicenter, randomized, double-blind, dose-escalation study of belimumab involved 70 patients with mild-to-moderate SLE, of whom 36 received a single infusion of belimumab (at 1, 4 ...

In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

Belimumab combined with standard of care therapy is safe and effective for treating systemic lupus erythematosus. Belimumab combined with standard of care (SOC) therapy shows promising efficacy ...